{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:11:22Z","timestamp":1767165082288,"version":"build-2238731810"},"reference-count":19,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2014,2,26]]},"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionally, patients with schizophrenia-spectrum disorders not infrequently consume alcohol. Glucagon-like peptide-1 (GLP-1) has shown to improve glycaemic control and reduce alcohol intake among patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate whether the beneficial effects of GLP-1 analogues on glycaemic control and alcohol intake, in patients with type 2 diabetes, can be extended to a population of pre-diabetic psychiatric patients receiving antipsychotic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Trial design, intervention and participants:<\/jats:italic>\n                      The study is a 16-week, double-blinded, randomised, parallel-group, placebo-controlled clinical trial, designed to evaluate the effects of the GLP-1 analogue liraglutide on glycaemic control and alcohol intake compared to placebo in patients who are prediabetic, overweight (body mass index \u226527\u2005kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), diagnosed with a schizophrenia-spectrum disorder and on stable treatment with either clozapine or olanzapine.\n                      <jats:italic>Outcomes: The primary endpoint<\/jats:italic>\n                      is the change in glucose tolerance from baseline (measured by area under the curve for the plasma glucose excursion following a 4\u2005h 75\u2005g oral glucose tolerance test) to follow-up at week 16.\n                      <jats:italic>The secondary endpoints<\/jats:italic>\n                      include changes of dysglycaemia, body weight, waist circumference, blood pressure, secretion of incretin hormones, insulin sensitivity and \u03b2 cell function, dual-energy X-ray absorption scan (body composition), lipid profile, liver function and measures of quality of life, daily functioning, severity of the psychiatric disease and alcohol consumption from baseline to follow-up at week 16.\n                      <jats:italic>Status:<\/jats:italic>\n                      Currently recruiting patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval has been obtained. Before screening, all patients will be provided oral and written information about the trial. The study will be disseminated by peer-review publications and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01845259\">NCT01845259<\/jats:ext-link>\n                      , EudraCT: 2013-000121-31.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2013-004227","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T22:17:40Z","timestamp":1395785860000},"page":"e004227","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial"],"prefix":"10.1136","volume":"4","clinical-trial-number":[{"clinical-trial-number":"nct01845259","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Julie Rask","family":"Larsen","sequence":"first","affiliation":[{"name":"Psychiatric Centre Copenhagen and Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Vedtofte","sequence":"additional","affiliation":[{"name":"Diabetes Research Division, Copenhagen University Hospital Gentofte, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[{"name":"Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Oturai","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kj\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U","family":"Corell","sequence":"additional","affiliation":[{"name":"Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[{"name":"Diabetes Research Division, Copenhagen University Hospital Gentofte, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Fink-Jensen","sequence":"additional","affiliation":[{"name":"Psychiatric Centre Copenhagen and Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,3,25]]},"reference":[{"key":"2025121509093176000_4.3.e004227.1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De","year":"2011","journal-title":"World Psychiatry"},{"key":"2025121509093176000_4.3.e004227.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156"},{"key":"2025121509093176000_4.3.e004227.3","doi-asserted-by":"publisher","DOI":"10.3109\/08039488.2011.565799"},{"key":"2025121509093176000_4.3.e004227.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.10.010"},{"key":"2025121509093176000_4.3.e004227.5","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"2025121509093176000_4.3.e004227.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-0115(03)00111-3"},{"key":"2025121509093176000_4.3.e004227.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61375-1"},{"key":"2025121509093176000_4.3.e004227.8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2337\/diabetes.53.2.294","article-title":"Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes","volume":"53","author":"Holten","year":"2004","journal-title":"Diabetes"},{"key":"2025121509093176000_4.3.e004227.9","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.85"},{"key":"2025121509093176000_4.3.e004227.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.03.017"},{"key":"2025121509093176000_4.3.e004227.11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1214530","article-title":"A behavioral weight-loss intervention in persons with serious mental illness","volume":"368","author":"Daumit","year":"2013","journal-title":"N Engl J Med"},{"key":"2025121509093176000_4.3.e004227.12","doi-asserted-by":"crossref","unstructured":"Mukundan A Faulkner G Cohn T . Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010;(12):CD006629.","DOI":"10.1002\/14651858.CD006629.pub2"},{"key":"2025121509093176000_4.3.e004227.13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.schres.2011.01.022","article-title":"The association between weight change and symptom reduction in the CATIE schizophrenia trial","volume":"128","author":"Hermes","year":"2011","journal-title":"Schizophr Res"},{"key":"2025121509093176000_4.3.e004227.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"2025121509093176000_4.3.e004227.15","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.21"},{"key":"2025121509093176000_4.3.e004227.16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1900\/RDS.2011.8.339","article-title":"Therapy for obesity based on gastrointestinal hormones","volume":"8","author":"Bagger","year":"2011","journal-title":"Rev Diabet Stud"},{"key":"2025121509093176000_4.3.e004227.17","doi-asserted-by":"publisher","DOI":"10.3109\/09540261003689958"},{"key":"2025121509093176000_4.3.e004227.18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"2025121509093176000_4.3.e004227.19","unstructured":"Kalra S Kalra B Sharma A . Change in alcohol consumption following liraglutide initiation: a real-life experience. American Diabetes Association Scientific Sessions 2011, Abstract number: 1029\u2013P."}],"updated-by":[{"DOI":"10.1136\/bmjopen-2013-004227corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T00:00:00Z","timestamp":1430870400000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2013-004227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:09:37Z","timestamp":1765818577000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2013-004227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,25]]},"published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1136\/bmjopen-2013-004227"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2013-004227","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}